Medical Oncology

Dr. Engin Erdemoğlu

Doctor and researcher Acıbadem Ataşehir HastanesiAcıbadem Kartal Hastanesi İstanbul
Breast NeoplasmsCOVID-19
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • COVID-19 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: acibadem.com.tr.

  • Meme Kanseri
  • Akciğer, Akciğer Zarı Kanserleri (Mezotelyoma) ve Diğer Torasik Kanserler
  • Mide Kanseri
  • Prostat Kanseri
  • Yumurtalık (Over) Kanseri
  • Baş Boyun Kanserleri
  • Pankreas Kanseri
  • Endometrial Kanser
  • Kemik Tümörleri
  • Kolorektal Kanserler (Kolon ve Rektum Kanseri)
  • Akciğer Kanseri
  • Kolon (Kalın Bağırsak) Kanseri

CV

Education and experience

From source

Experience

  • 2026Acıbadem Sağlık Grubuacibadem.com.tr
  • 2025İstanbul Onkoloji Hastanesi - Onkoloji Uzmanıacibadem.com.tr
  • 2023 - 2025Osmaniye Devlet Hastanesi - Onkoloji Uzmanıacibadem.com.tr
  • 2020 - 2023Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi - Tıbbi Onkoloji Yan Dal Asistanıacibadem.com.tr
  • 2017 - 2020Ümraniye Eğitim Araştırma Hastanesi - Dahiliye Uzmanıacibadem.com.tr
  • 2014 - 2017Mardin Devlet Hastanesi - Dahiliye Uzmanıacibadem.com.tr
  • 2009 - 2014Göztepe Eğitim ve Araştırma Hastanesi - Dahiliye Asistanıacibadem.com.tr

Education

  • 2023İstanbul Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji, Uzmanlıkacibadem.com.tr
  • 2014Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
  • 2009İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Tıp Fakültesi, Üniversiteacibadem.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologyacibadem.com.trFrom source
  • InstitutionAcıbadem Ataşehir Hastanesi, Acıbadem Kartal Hastanesiacibadem.com.trFrom source
  • Area of workBreast NeoplasmsExtracted from 2 publications · Model version —From source
  • Publications12 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-9235-8370ORCIDFrom source
  • Last synchronised4 November 2026 21:17https://www.acibadem.com.tr/doktor/engin-erdemoglu/acibadem.com.tr

Scientific work

Publications on Breast Neoplasms

12 publications
Publications by year Most: 4, in 2026
  1. 2014: 2 publications
  2. 2015: 1 publication
  3. 2016: 0 publications
  4. 2017: 0 publications
  5. 2018: 0 publications
  6. 2019: 0 publications
  7. 2020: 0 publications
  8. 2021: 0 publications
  9. 2022: 1 publication
  10. 2023: 2 publications
  11. 2024: 0 publications
  12. 2025: 2 publications
  13. 2026: 4 publications

  1. Chemotherapy Response Score and Survival Outcomes After Neoadjuvant Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma: A Multicenter Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62091688 PMID 42796295 Open-access full textSource: OpenAlex

  2. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Open-access full textSource: OpenAlex

  3. Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

    Targeted Oncology, 2026

    DOI 10.1007/s11523-026-01261-w PMID 42907609 Source: OpenAlex

  4. CT-defined sarcopenia and outcomes in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors

    Frontiers in Medicine, 2026

    DOI 10.3389/fmed.2026.1943515 Open-access full textSource: OpenAlex

  5. Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-negative breast cancer

    Journal of Cancer Research and Clinical Oncology, 2025

    DOI 10.1007/s00432-025-06336-1 PMID 41014426 4 citations (Europe PMC) Open-access full textSource: ORCID

  6. THE ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF COLORECTAL CANCER

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-770-4_p131 Source: OpenAlex

  7. Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e17509 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  8. Psychological state and predictors of psychiatric morbidity in COVID-19 patients six weeks after discharge

    Archives of Psychiatric Nursing, 2023

    DOI 10.1016/j.apnu.2023.07.003 PMID 37813498 Open-access full textSource: ORCID

  9. Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study

    Future Oncology, 2022

    DOI 10.2217/fon-2021-1248 PMID 35081732 27 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. Frequency of coagulation test results being in the therapeutic range in patients using warfarin treatment,Varfarin tedavisi alan hastalarda koagülasyon testlerinin terapötik aralıkta olma oranı

    Medeniyet Medical Journal, 2015

    DOI 10.5222/mmj.2015.105 Open-access full textSource: ORCID

View all 12 publications